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Abstract
HIV testing among young Black MSM and transwomen (YBMSM/TW) is the gateway to biomedical HIV prevention or treatment. HIV self-testing (HST) is a method that may increase consistent HIV testing. TRUST, a brief, peer-based behavioral
intervention, was designed to increase uptake of consistent (every three months) HST among YBMSM/TW in New York City.
To test the efficacy of the intervention, we randomized 200 friend pairs into either the intervention condition (TRUST) or a
time and attention control condition. A modified intent-to-treat analysis found that self-reported HST at 3-month follow-up
was statistically significantly higher (uOR 2.29; 95% CI 1.15, 4.58) and at 6-month follow-up was marginally statistically
significantly higher (uOR 1.94; 95% CI 1.00, 3.75) in the intervention arm as compared with the control arm. There were
no statistically significant differences by arm at 9- or 12-month follow-up. TRUST, a culturally-congruent intervention to
increase HST among YBMSM/TW, had short-term impact on past-three month HST.
Clinical Trials Registration ClinicalTrial.gov NCT04210271.
Keywords HIV testing · HIV self-testing · Peer intervention · Black men who have sex with men (MSM) · Transwomen
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In the United States (US), HIV testing occupies a central
role in national and local strategies to curb the HIV epidemic
[1–4]. Individuals who receive a positive test result may be
linked to medical and social care; if a sustained undetectable
viral load is achieved through treatment, these individuals
cannot transmit the HIV virus to their sexual partners [5].
Importantly, delayed diagnosis is associated with poorer
health outcomes and increased mortality and health care
costs for those affected [6–9]. Those who test negative may
consider uptake of effective biomedical prevention options,
such pre-exposure prophylaxis (PrEP) or post-exposure
prophylaxis (PEP), alongside other acquisition risk reduction strategies [10]. Collectively, these approaches have the
potential for significantly reducing HIV incidence. Yet, the
Centers for Disease Control and Prevention (CDC) estimates that 80% of new infections occurring in 2016 were
transmitted from the approximately 40% of people living
with HIV who had not yet been diagnosed with HIV or who
received a diagnosis but were not in care [11]. Because of
this, in part, the CDC and others recommend consistent
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testing (approximately every 3–6 months) for members of
populations [12, 13] more vulnerable to HIV, including men
who have sex with other men as well as transgender women
(henceforth transwomen).
Gay, bisexual and other men who have sex with men
(henceforth MSM) and transwomen who have sex with men
continue to bear a disproportionate burden of HIV, with
67% of all new HIV diagnoses in the US occurring among
this group in 2016 [14]. Racial disparities in HIV infections
among MSM and transwomen remain stark, with Black and
Latino MSM representing the majority of new HIV infections [14]. Young Black MSM are six times more likely to
be unaware of their HIV infection, compared to other MSM,
and face significant structural barriers to testing [7, 15].
Further, some current research suggests that sexually active
Black MSM and transwomen could benefit from more frequent HIV testing [13]. Although HIV testing has increased
among Black MSM in recent years [16], further increases
in testing are needed to optimize uptake of biomedical and
behavioral prevention strategies and linkage to medical care
and uptake of ART early in HIV infection [17–22]. However, few HIV testing interventions designed specifically for
young Black MSM and transwomen have been designed and
tested [23, 24]. Further, the availability of novel HIV testing
approaches, such as self-testing for those unable or unwilling
to visit a testing site, offer opportunities for innovative testing interventions tailored to the needs of young Black MSM
and transwomen [25, 26].
HIV self-testing is a method that may increase consistent
testing by addressing user concerns around HIV stigma and
increasing control over testing timing and context [27, 28],
as well as well-founded mistrust of institutions or organizations based in lived experiences of racism and the legacy of
medical racism in the US [29–31]. Early concerns among
clinicians and HIV prevention/treatment professionals
included potential lack of test operator skill and need for
training, challenges with linkage to care, and risks inherent
in receiving test results alone and unsupported [32]. In our
previous research with Black MSM and transwomen, we
found that while HIV self-testing was an acceptable option,
potential users had concerns around cost, lack of support
following a positive result, and correct test operation [33].
Yet, our formative research, in conjunction with our practical
experience managing a large HIV testing program, also suggested that self-testing could be an empowering option that
could support autonomy and reduce anxiety associated with
contact with inhospitable or unsafe service contexts [27].
Moreover, a peer-based self-testing approach builds disclosure of a positive test result to a supportive social network
member into the testing process [34–36]. Given that social
support is associated with linkage to care and HIV testing, building social support into rapid self-testing may also
increase likelihood of care linkage [37, 38]. Our formative
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research found that HIV self-testing with a friend was an
acceptable option that addressed concerns around individuals receiving positive test results alone and unsupported,
potentially experiencing distress alone and/or decreasing
the chances of being linked to HIV care [27, 33, 39].
Based on our formative research, program implementation experience, and the literature, we developed a peerbased behavioral intervention to increase the uptake of rapid
HIV self-testing (every three months) among young Black
MSM and transwomen [39, 40]. We designed the intervention so that friend pairs could learn self-testing together and
support each other in future self-testing, as prior research
demonstrated that social support is associated with increased
testing among Black MSM [34, 35]. Additionally, because of
the concern that self-testers might receive a positive result
alone and unsupported, shared by both clinicians and potential self-test users, and thus be less likely to link to care, we
designed modules where participants identified the specific
peer support needed to facilitate linkage to care in the event
of an HIV diagnosis. Here, we present results of a randomized controlled pilot trial of the intervention to establish
preliminary efficacy.

Methods
Design
Eligible friend pairs, consisting of a “Primary Eligible
Participant” (PEP) and the “Friend of the PEP,” were randomized together to one of two conditions. In the intervention
condition (the TRUST intervention), friend pairs engaged
in HIV testing together as friends, using a standard counselor-administered fourth-generation rapid HIV test to establish HIV-negative status and a modified version of couples
testing for MSM [41], and included all standard HIV risk
reduction (e.g., modes of transmission, role of alcohol and
drug use, etc.) and HIV testing (e.g., window period, testing
options, etc.) content. Next, they participated in a 30-min
TRUST intervention session; namely, a psycho-educational
rapid HIV self-test training session, described in more
detail below, focused on mobilizing social support, enhancing motivation, increasing knowledge, and acquiring skills
to adopt and maintain consistent HIV testing, with focused
instruction on HIV self-testing and planning as a friend pair
for consistent self-testing and HIV prevention. The time
and attention control arm had the friend pairs test for HIV
separately, but share their test results prior to participating
in a 30-min didactic informational session on self-screening for common health conditions, such as hypertension,
diabetes, anxiety and depression, alcohol and drug abuse,
and testicular and anal cancer. The intervention and control arm sessions were delivered by trained peer educators
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and audio-recorded; the last author monitored fidelity to the
intervention by listening to every fifth session and providing
feedback on drift and contamination. Both session facilitators and participants knew to which study arm participants
were assigned.
Enrollment began in July of 2016 and ended in December of 2017, with the final follow-up surveys occurring in
January of 2019. Standardized web-based, self-administered surveys assessed outcomes and covariates at baseline
and 3-, 6-, 9-, and 12-months post baseline. Participants
received compensation at all study visits: $75 (baseline);
$30 (3/6/9 M); $40 (12 M). All participants were provided
HIV self-test kits at the baseline visit and at every follow-up
session, using a method of their choice (mailed to their home
or picked up at the site). This randomized pilot efficacy trial
tests the hypothesis that PEPs randomized to the TRUST
intervention were more likely to report consistent HIV selftesting, defined as self-testing in the past three months over
a 12-month period, as compared with PEPs randomized to
the time and attention control arm.
The institutional review boards at all participating institutions approved the study. A DSMB was convened, with
members independent of the trial and funding agency, to
monitor and support safe and effective conduct of the trial.

Participant Eligibility
Initially, PEPs and Friends of PEPs were eligible if they
were: (1) 18–29 years of age; (2) assigned male sex at birth;
(3) self-identified as Black, African American, Caribbean
Black, African Black, or multiethnic Black; (4) resided in
the NYC area; (5) were not HIV positive according to selfreport; (6) reported insertive or receptive anal intercourse
with a man or transwoman in the last 12 months; (7) were
willing to participate in a study for 12 months; (8) could
communicate in English; (9) provided informed consent,
including participating in the study with a friend and HIV
testing together or sharing test results. Participants were
ineligible if they were enrolled in any other HIV-related
research study involving HIV testing or have been a participant in an HIV vaccine trial.
After the pilot efficacy trial began, we made two changes
to the eligibility criteria for PEPs. In January of 2017, we
expanded the upper end of the age range criterion from 29 to
34, although the final sample accrued had an average of ~ 24
for both PEPs and Friend of PEPs. In addition, based on epidemiologic evidence showing stable infection rates among
Latino MSM [42], in July of 2017, we expanded the race/
ethnicity criterion to include individuals who self-identified
as Latino/a/x, but not Black or African American. We note
that despite this change, we did not enroll any participants
who identified as Latino and did not also identify as Black,
African-American, Afro-Caribbean or Black African. Thus,

all of the PEPs enrolled indicated that they were Black,
African-American, Afro-Caribbean or Black African, either
only or in addition to indicating another “race/ethnicity”.
We also adjusted the Friend of PEP criteria in late 2016;
we determined that a number of eligible individuals would
have enrolled in the study, as PEPs, if they had been able
to include a friend who fell outside the original eligibility
criteria for Friends of PEPs, for example, a cisgender female
friend. Thus, in July 2016, we expanded the criteria for the
Friend of PEP so that eligibility included only: 18 years of
age or older; HIV negative; and able to communicate in English; these individuals must also have been willing and able
to provide informed consent, including HIV testing with a
friend and/or sharing test results.

Recruitment and Sample Accrued
Recruitment was conducted via online advertising, face-toface outreach and referrals by study participants. For online
recruitment, individuals clicked on an ad and completed a
brief eligibility assessment. If they were eligible and interested in participating in the study with a friend, they completed an online contact card and were provided a link that
they could send to a friend to complete the eligibility survey,
indicate their interest in participating, and provide contact
information. The study staff then retrieved this information and contacted both friends to schedule a study visit.
In face-to-face recruitment, potentially eligible individuals
were informed about the study and completed a preliminary
eligibility assessment. Eligible participants were then asked
to provide contact information for study staff follow-up.
Finally, eligible and enrolled participants were encouraged
to refer up to five people for the study and receive $10 for
each person who completed the screening process and was
found to be eligible for the study. When an eligible PEP and
their eligible friend were matched and both identified a baseline enrollment date, the appointment was made. Both PEPs
and their friends confirmed their understanding that, at the
baseline enrollment visit, they would be tested for HIV and
that their friend would learn the results of the test at the visit.
Among 3143 potential participants who landed on the
web-based eligibility screening page, 2579 began the PEP
screener. Of these, 451 were determined to be eligible as
PEPs and 434 indicated that they were interested in participating in the study. However, of these, 372 provided adequate contact information for study staff to contact them.
These eligible and interested PEPs were instructed (either
by study staff or as described in the web-based instruction)
to e-mail and/or text a unique Friend of PEP web-based eligibility screener link. This resulted in 434 Friend of PEPs
starting the web-based eligibility screener, with 353 being
eligible and providing adequate contact information. Once
matched, as described above, a total of 200 unique friend
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pairs or 400 individuals (PEPs and Friend of PEPs) attended
the baseline visit and were randomized (See Fig. 1).

Baseline Visit Procedures
After both participants arrived at the site, they engaged in
the informed consent process and were asked to provide
contact information to assist with study retention. After
the informed consent process was complete, participants
were randomized as friend pairs in a 1:1 ratio into either
the TRUST intervention or the time- and attention-matched
control intervention arm using assignments generated by the
study data analyst using Sealed Envelope Ltd. 2015 [available from: https://www.sealedenvelope.com/simple-rando
miser/v1/lists (Accessed 4 Mar 2016)]. Assignments were
in sequentially numbered, sealed, opaque envelopes, which
staff opened and recorded the pair’s study ID number and
assignment into the site’s data management system. Neither
staff nor participants were blinded to study arm assignment.
Participants then completed the baseline assessment via
ACASI, which assessed sociodemographic characteristics,
HIV testing history (including self-testing) [43], sexual
behaviors, [44] substance use behaviors [45, 46], mental
health indicators [47], peer support and engagement with
study friend, and other psychosocial factors (e.g., health
empowerment, internalized stigma, experiences of racial discrimination [48]) in the prior three months. Questions about
sexual behaviors in the prior three months included number
of anal or vaginal sex partners, insertive and receptive anal
sex, condom use and HIV status of partners. Questions on
use of substances in the prior three months included marijuana, stimulants (powder cocaine, crack cocaine, methamphetamine), prescription drugs, poppers, erectile dysfunction
drugs, and club drugs. After completing the baseline assessment, participant pairs randomized to the intervention arm
engaged in standard HIV testing and counseling together
as a friend pair and the TRUST intervention session. Participant pairs randomized to the time and attention control
arm received standard HIV testing and counseling separately
and then came together, sharing their test results; they then
engaged in the generic self-screening time and attention
control arm. After the baseline study visit was complete,
each participant received $75 cash and a round-trip transit
fare card.

Intervention and Control Arms
The TRUST intervention was developed using a formative
mixed methods research phase including in-depth interviews
(N = 29) and quantitative surveys (N = 433) to explore relevant domains and evaluate interest in the core intervention mechanisms of self-determined and peer supported
HIV self-screening [40]. Results informed the design of
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the TRUST intervention, which was framed broadly within
socioecological [49], empowerment [50–52], self-efficacy
[53] and social support [54] theories, and incorporated core
components of motivational interviewing theory [55], specifically exercises to address decisional balance associated
with HIV testing [23, 56]. A brief pre-pilot phase enrolled
eight friend pairs, after which the TRUST intervention
condition was finalized. In this arm, after HIV testing and
receiving results together, participant pairs assigned to the
TRUST intervention condition engaged in the structured,
interactive session that included the following components:
(1) Describing their optimal sex life and how HIV testing fit
into that; (2) HIV self-testing instruction (e.g., specific and
clear instructions on how to operate the self-test; common
mistakes and ways to avoid them, etc.); (3) HIV self-test
skills building (e.g., peers taught each other how to operate
the HIV self-test); (4) identifying and communicating the
specific peer support needed to support consistent testing
and receipt of test results; (5) planning for risk reduction
and consistent self-testing and/or testing over time (together
or apart). At the end of the session, participants developed
personalized “Staying Negative” plans, specifying how to
support each other in staying negative including through
self-monitoring and -testing; finally, they selected their selftest delivery approach (mailed to their homes or picked up
from the site). Participants were encouraged to support each
other in enacting their testing plans, but there were no formal
intervention components delivered by staff to the intervention arm pairs after the baseline session.
Time and attention control participant pairs were HIV
tested separately, but received their results together, and then
were provided the control condition, which offered information about a range of self-screening approaches for common,
adverse health conditions, such as testicular cancer, anal cancer, high blood pressure, diabetes, anxiety and depression,
alcohol and drug abuse, and HIV. In the control arm, each
health condition and available self-screening methods were
described didactically.
To reduce the potential bias of the cost of self-test kits as
a factor in future HIV testing, all intervention and control
participants received two HIV self-test kits at the end of
the baseline visit and received free HIV self-test kits every
3 months via their preferred delivery method. There were
no other control arm components delivered to control arm
participants beyond the baseline session.
Training of peer educator-facilitators for both arms covered study purpose, ethics, privacy, confidentiality, procedures, and implementation and was delivered by the project
investigators. Peer educators-facilitators also received clinical supervision to address issues that may have arisen during
delivery of the sessions. Fidelity to the intervention and control arms was monitored via review of a random selection of
audio recordings using a standardized form with qualitative
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Fig. 1  TRUST study consort flow diagram: primary eligible participants only
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feedback provided to the peer educator-facilitators throughout the duration of the project.

Outcome Assessment: Follow‑Up Surveys and Access
to HIV Self‑Test Kits
The primary outcome was self-reported consistent HIV
self-testing, defined as self-testing for HIV within the past
three months, over 12 months of follow-up. The primary
outcome and covariates were assessed via follow-up surveys completed by participants either online or at the study
site via ACASI. Participants were sent a link to the followup surveys by email, which they could complete remotely.
Alternatively, participants could come into the study site
to complete the follow-up survey. The follow-up assessment included the same questions as in the baseline survey,
excluding some sociodemographic information. After the
final survey at 12 months, participants who reported testing
HIV positive in one of the follow-up surveys were contacted
to ensure that they received medical and social care; at each
point of contact, all participants were informed that study
staff were available to provide resources for linkage to care
and social services, as needed for HIV or otherwise.

Power and Statistical Analysis
The study was powered for a treatment effect for the primary
binary outcome, consistent HIV self-testing (i.e., every three
months) according to self-report. Our initial power calculation, with a 20% difference between the two arms (40% selftesting in the intervention arm and 20% in the control arm;
95% plausible interval for control values 10%, 30%), indicated
that a sample size of approximately 188 participants (about 94
pairs) were required in each study arm to achieve ~ 80% power
(p < 0.05) [57]. Analysis of outcomes among PEPs only were
conducted on a modified intent-to-treat basis using subjects
who were eligible and for whom we were able to collect data.
After randomization, one PEP participant was discovered to
have enrolled in another HIV testing study at the study site and
was removed from the study. Because HIV testing was part
of both arms of the study, a number of participants (N = 18;
13 Friend of PEPs and 5 PEPs) were found to be HIV positive after randomization. In consultation with our Institutional
Review Board (IRB) and Data and Safety Monitoring Board
(DSMB), we determined that these individuals could not continue in the study despite having been randomized due to the
ethical imperative that we immediately support test result confirmation and linkage to medical and social care. When the
participant who tested positive was a Friend of PEP, the PEPs
(N = 13) continued in the study, despite not having received the
full session, due to the receipt of the reactive test result, and
were included in the modified intent to treat analysis. Thus,
there were 19 randomized individuals who had baseline data
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but no follow-up data and thus were not included in what
became a modified intent to treat analysis. Of the 381 remaining participants, 190 were PEPs and were included in the analytic dataset; unfortunately, baseline data for two of these PEPs
were lost due to a computer malfunction, leaving 188 PEPs in
the analytic dataset (90 in the TRUST intervention arm and 98
in the control arm).
Using this sample, our analysis unfolded in several steps
based on prior research [43]. First, descriptive analyses were
conducted to assess randomization. Here, for two-group
comparisons of continuous measures, Wilcoxon rank sum
tests were implemented; for ordinal measures, the CochranArmitage test for trend was used to compare baseline characteristics across study arms. In addition, dropouts were
compared to completers by baseline behavior and other characteristics to assess whether differential dropout occurred.
Generalized estimating equation models using an independent structure and with subject as a cluster were used to assess
reported changes from baseline to 3-, 6-, 9-, and 12-month
follow-up, excluding participants who reported an HIVpositive test result at any follow-up period. An interaction
term that concatenated treatment group and wave was used
to calculate odds of HIV self-testing for the intervention arm
participants compared with the control group participants.
The primary outcome, self-reported occurrence of HIV selftesting by the PEP in the past three months, was compared
between intervention and control arms.
We planned to adjust for variables in the final model that
were associated at baseline with both study arm (indicating
that randomization was suboptimal) and the study outcome,
self-reported HIV self-testing in the past three months, using
a statistical significance cut point of p < 0.10. Based on this
strategy, we assessed associations among baseline variables
that met that criteria (i.e., full-time employment vs. other
and AUDIT score) and our outcome HIV self-testing in the
past three months. We ran the final test of the intervention
GEE model with each factor and then compared the models
and found that the inclusion of the covariates did not significantly improve the model fit (and the covariates were not
statistically significant in the model). Thus, we present the
most parsimonious model for the test of the intervention’s
effect in an unadjusted model. Finally, we conducted exit
interviews with all participants who reported a reactive or
indeterminate test results during the follow-up period and
who we could locate to ensure that they were connected to
HIV care.

Results
The mean age of PEPs was 23.4 years (SD = 3.5 years).
Most (85.6%) self-identified as cisgender male; 11.7% as
a transwoman; and 2.1% as female. Three-fifths (59.9%)
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self-identified as gay or same gender loving and nearly
a third (30.3%) as bisexual; just one in ten (10.1%) were
employed full-time and over half (65.4%) earned less than
$10,000 per year. Almost three-quarters (73.4%) had a high
school degree, GED, or a lower level of education (Table 1).
In the three months before baseline, nearly a third (32.5%)
reported condomless receptive anal intercourse and 38.8%
reported condomless insertive anal intercourse. Over half
(53.7%) reported sex while using drugs in the past three
months and 16.5% reported five or more casual male or
transwoman sexual partners in the past 3 months. Just 6.4%
reported a new STI in the past 12 months and 9% were on
PrEP (Table 2). No statistically significant differences at
p < 0.10 were found between intervention and control arm
participants on key demographic or behavioral characteristics, except for employment (16% vs. 5%, Χ2 statistic = 5.88,
1 df, p = 0.02) and mean AUDIT scale scores (9.8 vs. 7.7;
Χ2 statistic = 0.989, 1 df p < 0.05). Five or more partners (Χ2
statistic = 2.90, 1 df) and worry about HIV (Χ2 statistic = 2.0,
1 df) were associated at p > 0.10.
At baseline, most participants (92.5%) reported lifetime
HIV testing and just less than half (43.1%) reported HIV
testing in the past 3 months. Less than one in five (14.4%)
reported lifetime HIV self-testing, although a third of these
participants had self-tested in the three months prior to
enrollment. Almost half of participants (45.2%) indicated
that they were very likely to self-test in the next three
months. Differences in past three months HIV self-testing
did not vary significantly by arm (Table 3).
Retention rates for both PEPs and Friends of PEPs
over the follow-up period were: 89% at 3-month, 83% at
6-month, 81% at 9-month and 82% at 12-month follow up
visits. Retention for PEPs only, were 79% at 3-month, 80%
at 6-month, 63% at 9-month and 88% at 12-month follow up
visits. Those PEPs not completing 3-month follow-up were
more likely to be financially insecure (p ≤ 0.001), unemployed (p = 0.004), and to have lower incomes (p = 0.014)
at baseline. There were no differences in lifetime or prior
3-month self-testing at baseline by retention at 3, 6, 9 and
12 months.
Self-reported HIV self-testing at 3- and 6-month follow-up was significantly higher in the intervention arm as
compared with the control arm. Participants in the TRUST
intervention arm had twice the odds of reporting HIV selftesting in the past three months at the 3-month follow-up
(uOR 2.29; 95% CI 1.15, 4.58) and almost twice the odds
at the 6-month follow-up point (uOR 1.94; 95% CI 1.00,
3.75). The proportion of participants in the TRUST intervention arm who reported self-testing was 2% at baseline
in the intervention arm, 57% at 3-months (p = 0.02), 54% at
6-months (p ≤ 0.05), 39% at 9-months (p = 0.34), and 48%
at 12-months (p = 0.49). This compares with the control arm
where self-testing was 7% at baseline, 42% at 3-months and

6-months, 39% at 9-months, and 41% at 12-months. The difference in past 3-month self-testing was statistically significant by arm at 3-month follow-up (p < 0.05) and was marginally statistically significant at 6-month follow up (p ≤ 0.05),
but were not statistically significant at 9- and 12-months
(Table 4).
Of the 188 PEPs, two reported testing HIV positive during follow-up. The participant who had been randomized to
the TRUST intervention arm reported using the HIV selftest to identify the new infection; the participant had been
randomized to the control condition did not report using the
self-test. Of note, another five Friends of PEPs self-reported
testing positive during the follow-up period; three had been
randomized to the control condition and two to the TRUST
intervention arm. None of these individuals reported using
the HIV self-test to identify the new infection.

Discussion
Increasing consistent HIV testing is a critical component of
the national prevention strategy in the US, where antiretroviral therapy and PrEP are available [58]. HIV self-testing
has taken on increased importance in the context of the
COVID-19 pandemic. [59] In this HIV self-testing RCT,
the intervention approach utilized peer support, motivational
enhancement and facilitated training approaches to increase
consistent HIV testing using the self-test. Self-testing
increased in both study arms among this sample; however,
intervention arm participants were more likely to self-test at
3- and 6-months post-intervention as compared with control
participants. Thus, the TRUST intervention demonstrated
efficacy to increase consistent self-testing, which conforms
to CDC recommendations for testing every three-to-six
months for higher-risk groups [60]. The control arm in this
study provided a strong test of the intervention, as it provided participants with information about HIV self-testing,
was delivered to friend pairs, and included the provision
of HIV self-test kits as baseline and every three months, to
control for HIV self-test kit access.
We found that the effect of the TRUST intervention
diminished over time within our study follow-up timeframe,
which may be due to several factors. The intervention may
have worn off, despite the follow-up contact required for
the study design. As well, there may have been regression
to the mean, a common occurrence in clinical trials [61].
Alternatively, it is possible that the effect of the intervention may have been evident over longer periods of time had
follow-up continued past 12 months. Further research is
needed to determine if more booster messages or sessions
could, in a cost-effective manner, extend the positive impact
of the intervention [24]. Also of importance is that the control arm’s rate of HIV self-testing increased dramatically.
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Table 1  Baseline sociodemographic characteristics by study arm, TRUST study 2016–18
Total

Intervention

Control

Primary
(N = 188)

Friend
(N = 188)

Primary
(N = 89)

Friend (N = 90) Primary
(N = 99)

Friend (N = 98)

Sociodemographics
23.4 (3.5)
Age (Mean,
SD)a

23.8 (5.7)

23.5 (3.7)

23.5 (4.8)

23.3 (3.4)

24 (6.4%)

4 (2.13%)
161 (85.6%)
22 (11.7%)

42 (22.7%)
118 (63.8%)
19 (10.3%)

2 (2.22%)
81 (90%)
6 (6.67%)

25 (26.6%)
56 (60.5%)
10 (10.6%)

2 (2.04%)
80 (81.63%)
16 (16.33%)

17 (18.7%)
61 (67%)
9 (9.9%)

1 (0.53%)

6 (3.2%)

1 (1.1%)

2 (2.1%)

0 (-)

4 (4.4%)

99 (53.5%)

88 (49.2%)

50 (56.18%)

48 (51.6%)

49 (51.04%)

40 (46.5%)

56 (30.3%)
13 (7.0%)
17 (9.2%)

54 (30.2%)
29 (16.2%)
8 (4.5%)

25 (28.09%)
7 (7.87%)
7 (7.87%)

24 (25.8%)
17 (18.3%)
4 (4.3%)

31 (32.29%)
6 (6.25%)
10 (10.42%)

30 (34.9%)
12 (14%)
4 (4.7%)

111 (59.9%)

103 (56.0%)

55 (61.8%)

51 (54.8%)

56 (57.1%)

52 (57.1%)

57 (30.3%)
3 (1.6%)

49 (26.6%)
2 (1.1%)

26 (29.2%)
3 (3.4%)

26 (28.0%)
1 (1.1%)

31 (31.6%)
0 (-)

23 (25.3%)
1 (1.1%)

16 (8.5%)

30 (16.3%)

5 (5.6%)

15 (16.1%)

11 (11.2%)

15 (16.5%)

137 (72.9%)

133 (73.1)

65 (73%)

64 (68.8%)

72(72.7%)

69 (77.5%)

124 (66%)

129 (70.1%)

56 (62.9%)

65 (69.9%)

68(68.7%)

64 (70.3%)

19 (10.11%)

22 (11.9%)

14 (15.56%)

12 (21.8%)

5 (5.1%)

10 (11%)

38 (20.5%)
52 (28.1%)

24 (26.67%)
16 (17.78%)

21 (22.3%)
26 (27.7%)

20 (20.41%)
23 (23.47%)

17 (18.7%)
26 (28.6%)

36 (9.5%)

28 (31.11%)

21 (22.3%)

22 (22.45%)

15 (16.5%)

Gender identity
Female
Male
Male to female
(MTF)
transgender
Other
Race/ethnicity
African-American
African/Other
Afro Latino
Caribbean
Sexual identity
Gay/same gender loving/
queer
Bisexual
Questioning or
unsure
Heterosexual/
straight/other
High school
education or
higher
Total personal
income less
than 10 K/year
Full-time
employment

Financial
insecurity (not
enough money
for food, rent,
etc.)
Never
44 (23.4%)
39 (20.74%)
Once in a
while (1–2
times)
Fairly often
50 (26.6%)
(3–5 times)
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Test statistic, df,
p-value

t-test statistic = 0.386,
186 df,
p-value = 0.700
Fisher’s exact test,
p-value = 0.122

Χ2 statistic = 0.996, 3 df,
p-value = 0.802

Fisher’s exact test,
p-value = 0.164

Χ2 statistic = 0.002, 1 df,
p-value = 0.962
Χ2 statistic = 0.694, 1 df,
p-value = 0.405
Χ2 statistic = 5.88, 1 df,
p-value = 0.018
Χ2 statistic = 4.21, 3 df,
p-value = 0.240
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Table 1  (continued)
Total

Intervention

Control

Primary
(N = 188)

Friend
(N = 188)

Primary
(N = 89)

Friend (N = 90) Primary
(N = 99)

Friend (N = 98)

Very often
(6 or more
times)
Health insurance

55 (29.26%)

59 (31.9%)

22 (24.4%)

26 (27.7%)

33 (36.3%)

Currently has
health insurance
Usual health
care

149 (79.26%)

Medical doctor’s office
Emergency
room
Community or
Free clinic,
HIV/STI
(sexually
transmitted
infection)
counseling
and testing
site, Health
department
Alternative
practitioner
(e.g., herbalist), Drug
treatment
program,
other
a

137 (74.1%)

73(82.0%)

65 (69.2%)

33 (33.67%)

76 (76.8%)

72 (79.1%)

76 (40.4%)

72 (38.9%)

37 (41.1%)

41 (43.6%)

39 (39.8%)

31 (34.1%)

47 (25.0%)

45 (24.3%)

26 (28.9%)

27 (28.7%)

21 (21.4%)

18 (19.8%)

57 (30.3%)

59 (32.1)

25 (27.8%)

23 (–)

32 (32.7%)

37 (40.7%)

8 (4.3%)

8 (4.3%)

2 (2.2%)

3 (3.2%)

6 (6.1%)

5 (5.5%)

Test statistic, df,
p-value

Χ2 statistic = 0.5, 1 df,
p-value = 0.480

Χ2 statistic = 3.11, 3 df,
p-value = 0.375

Primary: Minimum = 18; Maximum = 33. Friend: Minimum = 18; Maximum = 54

Statistical tests contrast Primary treatment assignment

b

Chi-square test not performed due to small cell counts

Because our study design controlled not only for time and
attention, but also for format (peer-based), core content
(awareness of the HIV self-test) and access (provision of
HIV self-tests every three months), it is not possible to indicate that a significantly shorter and less resource-intensive
intervention could achieve the same results. Further research
using a multi-factorial design could answer such a question.
HIV self-testing is a critical option that can help to
increase consistent HIV self-testing. The HIV self-test is
believed to reduce anticipated stigma that acts as an important barrier to HIV testing [62]. As well, HIV self-testing
allows users to test in privacy and on their own schedule.
However, HIV self-testing does not necessarily reduce fear
of a positive result and eventually reactive test results must
be confirmed using a second rapid test or other method. Fear

of this confirmation of HIV positive status may still prevent
individuals from accessing care [44]. It is possible that HIV
self-testing and/or consistent self-testing will increase openness to PrEP, through several mechanisms. The feelings of
increased self-efficacy to self-screen that may come from
consistent or even semi-annual use of an HIV self-test kit
may facilitate uptake of user-driven prevention methods,
such as PEP and PrEP. Future research could combine the
TRUST intervention with transition to PrEP components
embedded during the follow-up period to explore these
possibilities.
There are several key limitations to our study. First, our
outcomes were self-reported and increases in HIV selftesting may have reflected socially desirable responding;
this could have been more acute in the intervention arm,
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Table 2  Baseline sexual and drug use behavior and psychosocial factors by study arm, TRUST study 2016–2018
Total
Primary
(N = 188)

Intervention

Control

p-value

Friend
(N = 188)

Primary
(N = 89)

Friend (N = 90) Primary
(N = 99)

Friend (N = 98)

Sexual and drug use risk behavior
61 (32.5%)
Condomless
receptive anal
intercourse
P3M
73 (38.8%)
Condomless
insertive anal
intercourse
P3M
Sex while using 101 (53.7%)
drugs P3M

62 (33.5%)

26 (28.9%)

25 (26.6%)

35 (35.7%)

37 (40.7%)

Χ2 statistic = 1.14, 1 df,
p-value = 0.286

60 (32.4%)

36 (40%)

23 (24.5%)

37 (37.8%)

37 (40.7%)

Χ2 statistic = 0.02, 1 df,
p-value = 0.895

76 (41.1%)

49 (54.4%)

34 (36.2%)

52 (53.1%)

42 (46.2%)

New STI P12M

56 (30.6%)

52 (28.9%)

27 (28.7%)

48 (25.5%)

29 (32.6%)

16 (8.7%)

19 (21.11%)

7 (7.5%)

12 (12.24%)

9 (9.9%)

Χ2 statistic = 0.003, 1 df,
p-value = 0.957
Χ2 statistic = 0.04, 1 df,
p-value = 0.495
Χ2 statistic = 2.90, 1 df,
p-value = 0.102

1.9 (1.3)

2.0 (1.2)

1.7 (1.0)

2.0 (1.2)

2.2 (1.5)

3.2 (1.9)

3.6 (1.9)

3.0(1.9)

3.2 (2.0)

3.3 (1.9)

50 (27.7%)

31 (16.49%)
Five or more
casual male
and/or TGF
sex partners
HIV risk perception
How likely are 2.0 (1.2)
you to get
HIV?
3.4 (1.9)
How worried
are you about
getting HIV?

Χ2 statistic = 0.12, 1 df,
p-value = 0.729a
Χ2 statistic = 2, 1 df,
p-value = 0.101
a

Current PrEP
use

17 (9%)

20 (10.8%)

8 (8.9%)

6 (6.4%)

9 (9.2%)

14 (15.4%)

AUDIT score
mean (SD)

8.8 (5.9)

8.3 (4.7)

9.8 (6.5)

8.4 (5.1)

7.7 (5.1)

8.2 (4.3)

Χ2 statistic = 2.41, 1 df,
p-value = 0.120
Χ2 statistic = .989, 1 df,
p-value = 0.046
a

Drug use P3M
Marijuana

133 (70.7%)

122 (66.3%)

62 (69.7%)

66 (71.0%)

71 (71.7%)

56 (61.5%)

Stimulants

25 (13.3%)

17 (9.2%)

13 (14.6%)

6 (6.5%)

12 (12.1%)

11 (12.1%)

Club drugs/
poppers

32 (17.0%)

27 (14.7%)

17 (19.1%)

11 (11.8%)

15 (15.2%)

16 (17.6%)

Prescription/
other
Psychological Distress
(2-item PHQ:
low interest;
depressed)

17 (9.0%)

12 (6.5%)

12 (13.5%)

6 (6.5%)

5 (5.1%)

6(6.6%)

1.6 (0.8)

1.6 (0.8)

1.6 (0.7)

1.7 (0.9)

1.7 (0.9)

1.6 (0.7)
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Χ2 statistic = 0.096, 1 df,
p-value = 0.757
Χ2 statistic = 0.2511,
1 df,
p-value = 0.616
Χ2 statistic = 0.518, 1 df,
p-value = 0.472
0.969
Χ2 statistic = .016, 1 df,
p-value = 0.687
a
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Table 2  (continued)
Total

Mental Health
(2-item:
happy; calm
and peaceful)
Peer support
Outness (# of
friends know
gay/sex
with men/
attracted to
men or TGW
[none-all;
5-pt scale])
Peer norms @
safe sex &
testing (4-pt
scale)
HST Peer
Norms (most
friends
approve of
HST, etc.;
4-pt scale)
Social Support (count
on person;
accepts me;
trust with my
HIV results)
Health empowerment

Intervention

Control

p-value

Primary
(N = 188)

Friend
(N = 188)

Primary
(N = 89)

Friend (N = 90) Primary
(N = 99)

Friend (N = 98)

2.4 (1.1)

2.5 (1.3)

2.4 (1.1)

2.5 (1.4)

2.6 (1.3)

2.4 (1.1)

Χ2 statistic = .057, 1 df,
p-value = 0.812
a

3.6 (1.1)

3.5(1.1)

3.6 (1.0)

3.4 (1.1)

3.7 (1.1)

3.7(1.1)

Χ2 statistic = 0.486, 1 df,
p-value = 0.486
a

2.9 (0.7)

2.8 (0.7)

2.9 (0.7)

2.8 (0.8)

2.8 (0.7)

2.8 (0.7)

Χ2 statistic = 0.214, 1 df,
p-value = 0.643
a

3.3 (0.6)

3.2(0.6)

3.3 (0.6)

3.2 (0.6)

3.3 (0.6)

3.2 (0.6)

Statistic = 0.220,
1 df,
p-value = 0.639
a

3.5 (0.6)

3.4 (0.7)

3.5 (0.6)

3.4 (0.8)

3.4 (0.6)

3.5 (0.7)

Χ2 statistic = 0.481, 1 df,
p-value = 0.488
a

3.3 (0.5)

3.2 (0.5)

3.3 (0.5)

3.1 (0.6)

3.2 (0.5)

3.2 (0.4)

Statistic = 1.67,
1 df,
p-value = 0.196
a

Internalized
homophobia

1.7 (0.7)

1.7 (0.7)

1.8(0.7)

1.7 (0.7)

1.7 (0.7)

1.6 (0.7)

Statistic = 0.163,
1 df,
p-value = 0.687
a

a
#

Kruskal-Wallis test
Chi-square test not performed due to small cell counts

Statistical tests contrast the Primary’s treatment assignment groups

which focused intensively on HIV self-testing, although
self-screening for HIV with the self-test was described in
the control arm and control arm participants also received
HIV self-test kits every three months. Generalizability of
the findings was a limitation as the study was conducted
in New York City and limited to individuals who selfselected into the study and were willing to engage in HIV
testing with a friend. Further research is needed on HIV
self-testing acceptability and utilization for young Black
MSM and transwomen from other geographic regions in the
US, especially those areas that have high HIV incidence.
We observed loss to follow-up by select socioeconomic

characteristics. Although this did not vary by arm, it is concerning as it suggests that retention is compromised by poverty in this population. Although neither a new nor surprising finding [63], it speaks to the need to include intervention
strategies to support access to material resources and to keep
participants engaged over time in HST programming. The
recall period for study assessments may have influenced participants under- or over-reporting outcome variables. Along
this line, study participants may have known which arm they
were assigned to and may have engaged in socially desirable responding; however, we note that both arms received
information on HIV self-testing and test kits every three
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Table 3  Baseline HIV testing by study arm, TRUST study 2016–18
Total
Primary
(N = 188)
HIV testing
Ever HIV tested 174 (92.5%)
Number of
times tested
(lifetime)
1–2 times
3–4 times
5–9 times
10 or more
times
Most recent test
In the last
3 months
4–6 months
ago
7–12 months
ago
Don’t know
but in the last
year
More than
1 year ago
Don’t know
but more
than a year
ago

28 (16.1%)
44 (25.3%)
35 (20.1%)
67 (38.5%)

Intervention

Control

p-value

Friend
(N = 188)

Primary
(N = 89)

Friend (N = 90) Primary
(N = 99)

Friend (N = 98)

173 (93.5%)

83 (92.2%)

88 (93.6%)

91 (92.86%)

85 (93.4%)

42 (52.5%)
25 (31.2%)
12 (15.0%)
1 (1.2%)

12 (14.5%)
24 (28.9%)
15 (18.1%)
32 (38.5%)

21 (24.1%)
14 (16.1%)
26 (29.9%)
26 (29.9%)

16 (17.6%)
20 (22.0%)
20 (22.0%)
35 (38.5%)

14 (16.5%)
26 (30.6%)
20 (23.5%)
25 (29.4%)

84 (48.3%)

80 (46.2%)

40 (48.19%)

39 (44.3%)

44 (48.3%)

41 (48.2%)

47 (27.0%)

42 (24.3%)

20 (24.1%)

25(28.4%)

27 (29.7%)

17 (20%)

29 (16.7%)

17 (9.8%)

16 (19.28%)

4 (4.6%)

13 (14.3%)

13 (15.3%)

3 (1.7%)

4 (2.3%)

1 (1.2%)

1 (1.1%)

2 (2.2%)

3 (3.5%)

6 (3.4%)

26 (15%)

4 (4.8%)

16 (18.2%)

2 (2.2%)

10 (11.8%)

5 (2.9%)

4 (2.3%)

2 (2.4%)

3 (3.4%)

3 (3.3%)

1 (1.2%)

If not in P3M,
why?

N = 90

N = 93

N = 43

N = 49

N = 47

N = 44

It was not time for
me to test again
I think I’m at low
risk for HIV
I’m afraid to find
out I have HIV
I did not have time
I did not know
where to go for
a test
I did not have
enough money
or insurance for
a test
I did not want
other people to
know that I got
a test

30 (33.3%)

26 (28.0%)

9 (20.9%)

10 (20.4%)

21 (44.7%)

16 (36.4%)

16 (17.8%)

13 (14.0%)

5 (11.6%)

9 (18.4%)

11 (23.4%)

4 (9.1%)

7 (17.8%)

3 (3.2%)

3 (7.0%)

1 (2.0%)

4 (8.5%)

2 (4.5%)

27 (30.0%)
8 (8.9%)

22 (23.7%)
3 (3.2%)

15 (34.9%)
3 (7.0%)

10 (20.4%)
1 (2.0%)

12 (25.5%)
5 (10.6%)

12 (27.3%)
2 (4.5%)

3 (3.3%)

0 (–)

2 (4.7%)

0 (–)

1 (2.1%)

0 (–)

1 (1.1%)

1 (1.1%)

0 (–)

0 (–)

1 (2.1%)

1 (2.3%)
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Χ2 statistic = .01, 1 df,
p-value = 0.920
Χ2 statistic = 1.35, 3 df,
p-value = 0.719

Fisher’s exact test
p-value = 0.806

#
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Table 3  (continued)
If not in P3M,
why?

N = 90

N = 93

N = 43

N = 49

N = 47

N = 44

If I test positive, I
wouldn’t know
where to go for
treatment or how
to pay for it
If I test positive, I
will be rejected
by my friends or
family
I don’t want my
result reported
to the health
department
I had a bad experience the last
time I got tested
Other
HIV self–test
ever?

1 (1.1%)

3 (3.2%)

1 (2.3%)

1 (2.0%)

0 (–)

2 (4.5%)

3 (3.3%)

–

1 (2.3%)

0 (–)

2 (4.3%)

0 (–)

2 (2.2%)

2 (2.2%)

0 (–)

0 (–)

2 (4.3%)

2 (4.5%)

1 (1.1%)

0 (–)

0 (–)

0 (–)

1 (2.1%)

0 (–)

10
(11.1%)

4 (4.4%)

8 (18.6%)

2 (4.0%)

2 (4.3%)

2 (4.5%)

27 (14.4%)
161 (85.6%)

20 (10.6%)
168 (89.4%)

11 (12.2%)
79 (87.8%)

10 (1.1%)
80 (87.9%)

16 (16.3%)
82 (83.7%)

10 (10.2%)
88 (89.8%)

Yes
No
If HST ever,
what type?

N = 27

N = 20

N = 11

N = 10

N = 16

N = 10

HomeAccessÂ® HIV-1
Test System
OraQuickÂ®
In-Home HIV
Test (you swab
your mouth,
use the testing
device yourself and read
the results in
20 min)
SureCheckÂ®
HIV Home
Test
A test that is
used at testing
clinics or by
health professionals
I don’ know
Other
HST P3M?

1 (3.7%)

0 (–)

1 (9.1%)

0 (–)

0 (–)

0 (–)

23 (85.2%)

16 (80.0%)

9 (81.8%)

8 (80.0%)

14 (87.5%)

8 (80.0%)

0 (–)

4 (20.0%)

0 (–)

3 (30.0%)

0 (–)

1 (10.0%)

1 (3.7%)

0 (–)

0 (–)

0 (–)

1 (6.3%)

0 (–)

3 (11.1%)
1 (3.7%)

2 (10.0%)
0 (–)

1 (9.1%)
0 (–)

0 (–)
0 (–)

2 (12.5%)
1 (6.3%)

2 (20.0%)
0 (–)

Yes
No
HST intention

9 (4.8%)
179 (95.2%)

3 (1.6%)
182 (93.4%)

2 (2.2%)
88 (97.8%)

1 (1.1%)
93 (98.9%)

7 (7.4%)
91 (92.9%)

2 (2.2%)
89 (97.8%)

26 (13.8%)

18 (9.7%)

13 (14.4%)

10 (10.6%)

13 (13.3%)

8 (8.8%)

Very unlikely

#

Χ2 statistic = 0.64,
1 df, p–
value = 0.423

#

Fisher’s exact test
p-value = 0.173

Χ2 statistic = 2.15, 3 df,
p-value = 0.542
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Table 3  (continued)
If HST ever,
what type?

N = 27

N = 20

N = 11

N = 10

N = 16

N = 10

Somewhat
unlikely
Somewhat
likely
Very likely
HST intention?
(with buddy)

15 (8%)

36 (19.5%)

7 (7.8%)

21 (22.3%)

8 (8.2%)

15 (16.5%)

62 (33%)

65 (35.1%)

25 (27.8%)

34 (36.2%)

37 (37.8%)

31 (34.1%)

85 (45.2%)

66 (35.7%)

45 (53%)

29 (30.9%)

41 (40.8%)

37 (40.7%)

20 (12.4%)
17 (10.5%)

19 (12.9%)
17 (11%)

7 (9.2%)
9 (11.6%)

11 (14.9%)
8 (10.8%)

13 (15.3%)
8 (9.4%)

8 (11%)
9 (12.3%)

66 (40.7%)

55 (37.9%)

32 (42.6%)

28 (37.8%)

34 (51.5%)

27 (37%)

59 (36.4%)
3.2 (0.6)

56 (37.9%)
3.1 (0.6)

29 (37.7%)
3.3 (0.6)

27 (36.5%)
3.0 (0.7)

30 (35.3%)
3.1 (0.6)

29 (39.7%)
3.3 (0.6)

2.8(0.5)

2.9(0.5)

2.7(0.6)

2.8(0.6)

2.8(0.4)

2.9(0.5)

Very unlikely
Somewhat
unlikely
Somewhat
likely
Very likely
HIV test selfefficacy
HIV testing
knowledge

#

Χ2 statistic = 1.55, 3 df,
p-value = 0.671

Χ2 statistic = 2.71, 1 df,
p-value = 0.100a
Χ2 statistic = 0.606, 1 df,
p-value = 0.436
a

HIV testing
plan (“I have a
regular testing
plan”)
Strongly agree
Agree
Disagree
Strongly disagree

Χ2 statistic = 2.53, 3 df,
p-value = 0.470
79 (42.7%)
96 (51.89%)
6 (3.24%)
4 (2.16%)

71 (39.2%)
92 (50.8%)
9 (5%)
9 (5%)

43(48.31%)
42 (47.19%)
2 (2.25%)
2 (2.25%)

37 (39.8%)
47 (50.5%)
5 (5.4%)
4 (4.3%)

36 (37.5%)
54 (56.25%)
4 (4.17%)
2 (2.08%)

34 (38.6%)
45 (51.1%)
4 (4.6%)
5 (5.7%)

Statistical tests contrast the Primary’s treatment assignment groups

a

#

Kruskal-Wallis test
Chi-square test not performed due to small cell counts

Table 4  HIV self-testing outcomes by study arm, TRUST, 2016–2018
Comparison

Unadjusted odds ratio

95% Confidence interval

p-value

Intervention at 3 M vs control at 3 M
Intervention at 6 M vs control at 6 M
Intervention at 9 M vs control at 9 M
Intervention at 12 M vs control at 12 M

2.29
1.94
1.41
1.14

1.15, 4.58
1.00, 3.75a
0.69, 2.88
0.60, 2.14

0.0191
0.0498
0.3443
0.6915

Outcome: Last 3 month Self-testing (self-reported yes)
a

Exact 95% CI = 1.0005, 3.7534

months and all assessments were done via self-interview
on a computer (with an emphasis on the need for accurate
self-report), which may have mitigated against socially
desirable responding. In planning the study, we considered
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alternatives to self-reported outcome data to address this
concern; however, our formative research suggested that
options considered (e.g., mailing or photographing used test
paddles) were not well-received by participants.

AIDS and Behavior

Conclusions
This study is one of the first to demonstrate the efficacy
of a peer-based, theoretically-informed HIV self-testing
intervention for young Black MSM and transwomen. The
TRUST intervention had a positive impact on likelihood
of HIV self-testing at three and six months after the intervention. Our findings suggest the importance of enhancing
awareness of and access to HIV self-testing as a promising complementary method of increasing HIV testing
among subpopulations unlikely to test at all and/or test
consistently [64, 65]. HIV self-testing is a promising way
to acknowledge the diversity of testing preferences and
strengthen access to a broader set of prevention methods
for young Black MSM and transwomen.
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